Accord Plasma, a subsidiary of Intas Pharmaceuticals, announced the completion of its acquisition of Prothya Biosolutions Belgium BV and its subsidiaries, marking a significant step in strengthening the company’s global plasma therapy network.
The acquisition enhances Accord’s mission to expand access to life-saving plasma-derived medicines and meet rising global demand for critical therapies.
Prothya Biosolutions is one of Europe’s leading plasma fractionators, operating large-scale facilities in Amsterdam and Brussels, alongside plasma collection centers across Hungary. The company employs approximately 1,200 professionals and brings deep technical expertise and a strong operational foundation to Accord’s growing global portfolio.
The integration of Prothya within Accord Plasma represents a strategic expansion of Accord’s plasma manufacturing and research capabilities. By combining Prothya’s established European expertise with Intas’s advanced plasma fractionation infrastructure in India, Accord will accelerate the development, production, and delivery of plasma-derived medicinal products (PDMPs) to patients in multiple regions around the world.
The acquisition positions Accord Plasma as a leading global player in plasma-derived medicine manufacturing—an area increasingly recognized as essential to treating rare and chronic conditions such as immune deficiencies, hemophilia, and other plasma-related disorders. With enhanced global manufacturing capacity and expanded collection networks, Accord will be better equipped to deliver safe, effective, and affordable plasma therapies to underserved patient populations.
Accord Healthcare, headquartered in the United Kingdom, has grown into one of Europe’s fastest-expanding pharmaceutical companies, distributing medicines to over 85 countries. The company’s continued investments in plasma and biologic therapies reflect its long-term strategy to improve patient outcomes through innovation and accessibility.
This acquisition reinforces Accord’s vision of becoming a global leader in high-quality, patient-centered healthcare, combining agility, scientific expertise, and a mission-driven approach to make essential medicines available to those who need them most.
KEY QUOTE:
“Our goal is to ensure that patients who depend on plasma-derived therapies can access reliable and high-quality treatments. Together with Prothya, we are better positioned to address the growing global need for plasma-derived medicines, providing patients worldwide with critical, often under-prescribed therapies.”
Paul Tredwell, Global CEO of Accord Healthcare
